On April 10th, the 11th International Biomedical Technology Exhibition, BioCon China Expo 2024, grandly opened in Beijing. This event comprehensively extends upstream and downstream of the industry, gathering forces for tackling key challenges, and creating an innovative biomedical technology exhibition integrating 'professional exhibitions + biopharmaceutical industry forums + exclusive authoritative competitions + special activities in exhibition areas'.
Top 10 Innovative Companies in Annual Investment Value
List co-publishing party
At the site of this international technology event, the final selection results for the BioCon Awards 2024 were announced.Ruizhen Regenerative Medicine has won the 'Top 10 Innovative Companies with Annual Investment Value' award for its achievements in transforming scientific and technological achievements into practical applications and leading innovative technologies in the industry.
The award recognizes individuals or organizations within the industry in 2023Emerging biotech companies with the greatest market potential and investment value.
Dr. Lubin Yan, Deputy General Manager of Rui Zhen Regenerative Medicine, represented the company on stage to receive the award
About RuiZhen Regenerative Medicine
Guangzhou Ruizhen Regenerative Medicine Technology Co., Ltd. is committed to developing general-purpose off-the-shelf cell therapy products derived from induced pluripotent stem cells (iPSCs) for treating tumors and neurological diseases. The company has established a pipeline including iPSC reprogramming andCell library constructionThe technology for the differentiation and preparation of immune and neural cells, as well as the construction of genetically modified engineered iPSC cell lines, covers the entire process of iPSC cell therapy.
Currently, RuiZhen's iDA001 pipeline product for the treatment of Parkinson's disease has shown outstanding therapeutic effects in a primate PD model, with clinical scale scores improving to normal monkey levels one month after transplantation. RuiZhen's independently developed technology for the differentiation and preparation of dopamine precursor cells has been authorized, making it the first domestic company to obtain authorization for related invention patents.
In the development of an engineered iNK pipeline for large-scale mass production and allogeneic therapy, challenging solid tumor treatment, Rui Zhen Regenerative Medicine focuses on the high-purity differentiation and preparation of iNK, as well as multi-module functional enhancement gene modification of iPSC. Through the efforts of the R&D team, a high-purity differentiation technology for iNK has been established, and the first animal experiment of engineered iNK in China has been completed. ADCC-enhanced iNK has shown strong tumor clearance and recurrence inhibition effects.
Based on the company's existing technology, Ruizhen Regenerative Medicine also provides professional iPSC reprogramming services, as well as scientific research services for the production and preparation of iPSC-derived functional cells, exosomes, and organoids to pharmaceutical companies, medical institutions, and research institutions. These products have significant research value in areas such as disease mechanism studies, drug screening, and exploration of cell therapy methods.
About BioCon Awards
The 'BioCon Awards' are an authoritative biomedical award created by the Organizing Committee of BioCon China Expo. Leveraging a decade of accumulation by the BioCon brand, the 'BioCon Awards' have assembled an expert panel composed of industry authorities to fairly and justly select pioneering enterprises/organizations/personal representatives from various fields of the biotechnology industry across multiple dimensions.The 'BioCon Awards' aim to encourage various enterprises, organizations, and individuals in the biomedical industry chain to continuously strive for progress, innovate, and set new industry benchmarks oriented towards clinical value and driven by technological innovation, thereby promoting the continuous advancement of the biomedical industry.
As a strategic partner of the BioCon Awards ceremony, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') jointly announces the BioCon Awards 2024 winners with the organizers.
